pirtobrutinib
FDA Grants Accelerated Approval to Jaypirca for CLL and SLL
The FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly) for adults with chronic lymphocytic ...
DECEMBER 4, 2023
Jaypirca Approved for Relapsed or Refractory Mantle Cell Lymphoma
The FDA granted accelerated approval to pirtobrutinib (Jaypirca, Lilly) for relapsed or refractory mantle cell ...
FEBRUARY 10, 2023
Load more